Skip to content

SierraSil Joint Formula 14 as an Ergogenic Aid to Performance in Athletes

SierraSil as an Ergogenic Aid to Performance in Athletes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01932281
Enrollment
10
Registered
2013-08-30
Start date
2014-05-31
Completion date
2014-09-30
Last updated
2015-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Fatigue, Muscle Power

Keywords

muscle power, muscle fatigue, SierraSil

Brief summary

The purpose of this study is to examine whether supplementation with SierraSil can improve anaerobic power and reduce muscle fatigue in a group of well-trained athletes. A secondary purpose is to examine the effect of SierraSil on the severity of delayed onset muscle soreness.

Detailed description

This is a double blind, crossover, pilot study that will examine the effect of SierraSil supplementation on the determinants of human performance. Anaerobic capacity, muscle fatigue, the severity of delayed onset muscle soreness (DOMS) and markers of inflammation will be measured before and after 3 weeks of supplementation with SierraSil or placebo. There will be a 3 week washout period prior to the crossover to ensure SierraSil supplementation has no residual effect.

Interventions

DIETARY_SUPPLEMENTPlacebo

Sugar pill manufactured to mimic SierraSil 667 mg capsule

DIETARY_SUPPLEMENTSierraSil

SierraSil is a natural, mineral supplement currently used to improve joint health and function.

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
19 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* no contraindications to strenuous exercise

Exclusion criteria

* muscle or joint injury * taking any form of anti-inflammatory or pain medication * females due to the variability that might be introduced due to the phases of the menstrual cycle

Design outcomes

Primary

MeasureTime frame
change in total anaerobic capacitychange from baseline at 3 weeks

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026